There is a large volume of new data continuously being released about the optimal management of prostate cancer. It is essential for practicing radiation oncologists to know the latest data and be able to integrate it into daily practice.This activity will review the new data and standard of care for each disease state of prostate cancer. It will start with very low risk disease and go through intermediate risk, high risk, locally advanced, node positive, oligometastatic, and post-operative.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this live activity, attendees should be able to do the following:
1. Treat oligometastatic prostate cancer with radiation when appropriate.
2. Utilize Abiraterone with radiation for prostate cancer when appropriate.
3. Hypofractionate radiation for prostate cancer when appropriate.
Paul Nguyen, MD, is employed by Brigham and Women’s Hospital and receives compensation/remuneration/funding from Astellas, Augmenix, Boston-Seientific, Cota, and Janssen.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.